ATE266726T1 - CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG - Google Patents

CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG

Info

Publication number
ATE266726T1
ATE266726T1 AT96922399T AT96922399T ATE266726T1 AT E266726 T1 ATE266726 T1 AT E266726T1 AT 96922399 T AT96922399 T AT 96922399T AT 96922399 T AT96922399 T AT 96922399T AT E266726 T1 ATE266726 T1 AT E266726T1
Authority
AT
Austria
Prior art keywords
cdr
antibodies against
ßtissue
factorß
tissue factor
Prior art date
Application number
AT96922399T
Other languages
English (en)
Inventor
Linda K Joliffe
Robert A Zivin
Virginia L Pulito
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Application granted granted Critical
Publication of ATE266726T1 publication Critical patent/ATE266726T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96922399T 1995-06-07 1996-06-06 CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG ATE266726T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48012095A 1995-06-07 1995-06-07
PCT/US1996/009287 WO1996040921A1 (en) 1995-06-07 1996-06-06 Cdr-grafted anti-tissue factor antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE266726T1 true ATE266726T1 (de) 2004-05-15

Family

ID=23906739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96922399T ATE266726T1 (de) 1995-06-07 1996-06-06 CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG

Country Status (11)

Country Link
US (4) US7235380B1 (de)
EP (1) EP0833911B1 (de)
JP (1) JP4423680B2 (de)
AT (1) ATE266726T1 (de)
AU (1) AU716282B2 (de)
CA (1) CA2223491C (de)
DE (1) DE69632465T2 (de)
DK (1) DK0833911T3 (de)
ES (1) ES2231817T3 (de)
PT (1) PT833911E (de)
WO (1) WO1996040921A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
BR9909382A (pt) * 1998-04-03 2000-12-05 Chugai Pharmaceutical Co Ltd Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
EP1105475A1 (de) 1998-07-15 2001-06-13 Genentech, Inc. Proteinvarianten von gewebsfaktoren mit erhöhter affinität für koagulationsfaktor fvii/fviia
CA2387857A1 (en) 1999-10-27 2001-05-03 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof
EP1829535A3 (de) * 1999-10-27 2007-10-24 Tanox, Inc. Gewebefaktor-Antagonisten und Verfahren zu deren Verwendung
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2002078738A1 (fr) * 2001-03-26 2002-10-10 Koji Suzuki Agents ameliorant la rheologie sanguine
WO2003029295A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk A/S Human tissue factor antibodies
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
US20050255111A1 (en) * 2002-02-22 2005-11-17 Olle Korsgren Use of an inhibitor or antagonist against tissue factor
AU2003277832A1 (en) * 2002-10-31 2004-05-25 Novo Nordisk A/S Humanized tissue factor antibodies
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
CA2527621A1 (en) * 2003-05-30 2004-12-23 Centocor, Inc. Method of inhibiting tumor growth with anti-tissue factor antibodies
US20050106147A1 (en) * 2003-08-29 2005-05-19 Robert Jordan Method of promoting graft survival with anti-tissue factor antibodies
US7514539B2 (en) 2004-04-26 2009-04-07 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
US7790405B2 (en) 2004-04-26 2010-09-07 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
EP1749536A1 (de) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Aktivierte Stimulatoren des Faktors X als antihämorrhagisches Mittel für die topische Anwendung
CA2621236A1 (en) 2005-08-31 2007-03-08 Centocor, Inc. Host cell lines for production of antibody constant region with enhanced effector function
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
EP2271670B1 (de) * 2008-03-14 2014-09-03 Allergan, Inc. Immunbasierte aktivitätsassays von botulinum-toxin serotyp a
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
ES2647388T3 (es) 2010-06-15 2017-12-21 Genmab A/S Conjugados farmacológicos de anticuerpos humanos contra factor tisular
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
US20120264710A1 (en) * 2011-04-15 2012-10-18 Marit Liland Sandvold Systems and Methods for Detecting hENT1 Expression in Hematological Disorders
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
EP3474854A4 (de) 2016-06-27 2020-02-19 The Regents of The University of California Krebsbehandlungskombinationen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU5093593A (en) * 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
BR9909382A (pt) 1998-04-03 2000-12-05 Chugai Pharmaceutical Co Ltd Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
EP1263960A2 (de) 2000-03-16 2002-12-11 Genentech, Inc. Antikörper gegen gewebefaktor (tf) mit erhöhter antikoagulierender wirkung

Also Published As

Publication number Publication date
WO1996040921A1 (en) 1996-12-19
JPH11507524A (ja) 1999-07-06
PT833911E (pt) 2004-09-30
DE69632465D1 (de) 2004-06-17
DE69632465T2 (de) 2005-06-23
EP0833911A1 (de) 1998-04-08
US20080226628A1 (en) 2008-09-18
US20100298544A1 (en) 2010-11-25
US20070238869A1 (en) 2007-10-11
CA2223491C (en) 2010-08-10
DK0833911T3 (da) 2004-08-30
JP4423680B2 (ja) 2010-03-03
ES2231817T3 (es) 2005-05-16
AU716282B2 (en) 2000-02-24
US7235380B1 (en) 2007-06-26
AU6328296A (en) 1996-12-30
US7777018B2 (en) 2010-08-17
EP0833911B1 (de) 2004-05-12
US7544790B2 (en) 2009-06-09
CA2223491A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
ATE266726T1 (de) CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
BG110703A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
DE69833779D1 (de) Verfahren und zusammensetzungen zur immunomodulation
NZ596723A (en) Human antibodies that bind human il-12 and methods for producing
BRPI0508716A (pt) anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal
ATE348113T1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
DE59504579D1 (de) Verfahren zur validierung und/oder kalibration von vorrichtungen zur fotometrie lebender gewebe sowie vorrichtung zur durchführung des verfahrens
EP2228389A3 (de) Antikörper gegen vaskulären Endothelwachstumsfaktor 2
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
WO2002083849A3 (en) Vascular endothelial growth factor 2
DK1265928T3 (da) RSV-neutraliserende antistoffer med ultra høj affinitet
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE50111926D1 (de) Strahlungsanordnung sowie deren Verwendung und Verfahren zur Behandlung von Oberflächen
UA41984C2 (uk) Спосіб інгібування утворення тромбів у людини (варіанти), спосіб лікування людини для зниження у людини небезпеки постхірургічних тромботичних ускладнень (варіанти),спосіб лікування тромботичного судинного захворювання у людини (варіанти), фармацевтична композиція, що містить некон'юговане антифібринове моноклональне антитіло мн-1, фармацевтична композиція, що містить некон'югований фрагмент або похідне антифібринового моноклонального антитіла мн-1, набір для лікування людини, що потребує інгібування утворення тромбу
DE60208534D1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
MX9709636A (es) Anticuerpos de factor antitisular, injertados en regiones determinadoras de complementariedad, y metodos para su uso.
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE60020353D1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0833911

Country of ref document: EP